Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab

被引：1
|
作者：
Masamoto, Yosuke [1 ]
Taoka, Kazuki [1 ]
Maki, Hiroaki [1 ]
Kurokawa, Mineo [1 ,2 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan
[2] Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Tokyo, Japan
来源：
ANNALS OF HEMATOLOGY | 2022年 / 101卷 / 12期
关键词：
Follicular lymphoma; Obinutuzumab; Infusion-related reactions; Risk factors; RITUXIMAB INFUSION; MULTICENTER;
D O I：
10.1007/s00277-022-04987-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2795 / 2797
页数：3
相关论文
共 50 条
  • [41] Utilizing a novel four-drug regimen to reduce the incidence of infusion-related reactions for first-dose rituximab infusions: An institutional review of rituximab infusion-related reactions in lymphoma patients.
    Bartels, Trace
    Moore, Logan
    Persky, Daniel Oscar
    Kumar, Abhijeet
    Abraham, Ivo
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Bone marrow involvement in AIDS-related lymphoma
    Troe, TE
    Ozer, O
    Fidler, MJ
    Okonkwo, A
    Variakojis, D
    LABORATORY INVESTIGATION, 2003, 83 (01) : 256A - 256A
  • [43] Bone marrow involvement in AIDS-related lymphoma
    Troe, TE
    Ozer, O
    Fidler, MJ
    Okonkwo, A
    Variakojis, D
    MODERN PATHOLOGY, 2003, 16 (01) : 256A - 256A
  • [44] Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma
    Faqeer, Nour
    Alrabie, Rawaa
    Al-Haddadin, Rand
    Ma'koseh, Mohammad
    JOURNAL OF CHEMOTHERAPY, 2024, 36 (04) : 291 - 298
  • [45] A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma
    Tsutsumi, Daisuke
    Hayama, Tatsuya
    Miura, Katsuhiro
    Uchiike, Akihiro
    Tsuboi, Shinya
    Otsuka, Susumu
    Hatta, Yoshihiro
    Kishikawa, Yukinaga
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 366 - 373
  • [46] Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study
    Park, Keunchil
    Sabari, Joshua
    Haura, Eric B.
    Shu, Catherine A.
    Spira, Alexander
    Salgia, Ravi
    Reckamp, Karen L.
    Sanborn, Rachel E.
    Govindan, Ramaswamy
    Bauml, Joshua M.
    Curtin, Joshua C.
    Xie, John
    Roshak, Amy
    Lorenzini, Patricia
    Millington, Dawn
    Thayu, Meena
    Knoblauch, Roland E.
    Cho, Byoung Chul
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S482
  • [47] Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma
    Canales, Miguel A.
    Buchholz, Thomas A.
    Mason, James R.
    Parreira, Joana M.
    Tomiczek, Monique S.
    Hubel, Kai
    BLOOD, 2019, 134
  • [48] Infusion-related reactions in patients receiving pertuzumab and trastuzumab: A retrospective study
    Loirat, Delphine
    Logeart, Juliette
    Vaflard, Pauline
    Noret, Aurelien
    Saint-Ghislain, Mathilde
    Borcoman, Edith
    Hurgon, Audrey
    Cros, Cyrille
    Genevee, Thomas
    Bellesoeur, Audrey
    Ricci, Francesco
    Lerebours, Florence
    Escalup, Laurence
    Sablin, Marie-Paule
    Bidard, Francois-Clement
    Cottu, Paul H.
    Pierga, Jean-Yves
    CANCER RESEARCH, 2022, 82 (04)
  • [49] A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma
    Daisuke Tsutsumi
    Tatsuya Hayama
    Katsuhiro Miura
    Akihiro Uchiike
    Shinya Tsuboi
    Susumu Otsuka
    Yoshihiro Hatta
    Yukinaga Kishikawa
    International Journal of Clinical Pharmacy, 2022, 44 : 366 - 373
  • [50] PREMEDICATION AND THE INCIDENCE AND SEVERITY OF INFUSION-RELATED REACTIONS IN PATIENTS TREATED WITH CETUXIMAB: DATA FROM THE CRYSTAL AND MABEL STUDIES
    Wilke, H.
    Siena, S.
    Loos, A.
    Berghoff, K.
    Koehne, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 71 - 72
12345